BridgeBio Pharma
BBIO
213 hedge funds and large institutions have $2.53B invested in BridgeBio Pharma in 2023 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 76 increasing their positions, 58 reducing their positions, and 24 closing their positions.
167% more funds holding in top 10
Funds holding in top 10: 3 → 8 (+5)
146% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 24
130% more capital invested
Capital invested by funds: $1.1B → $2.53B (+$1.43B)
31% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 58
19% more funds holding
Funds holding: 179 → 213 (+34)
3% more call options, than puts
Call options by funds: $53.7M | Put options by funds: $52M
1.57% less ownership
Funds ownership: 96.72% → 95.15% (-1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$37.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.3M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$15M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$43.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$30.2M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$14.1M |
| 4 |
AIG
American International Group
New York
|
-$11.8M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$9.78M |
BBIO Hedge Fund Activity: Q1 2023 in Review
213 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q1 2023, worth a combined $2.53B — up 130% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new BBIO positions and 24 closed out — a net gain of 35 holders — while 76 added to existing stakes and 58 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $37.2M. The largest seller was State Street, cutting an estimated $43.2M.
- 213 institutional investors held BridgeBio Pharma (BBIO) as of Q1 2023, up from 179 in Q4 2022.
- Funds reported $2.53B of BridgeBio Pharma stock for Q1 2023, up 130% quarter-over-quarter.
- 59 funds opened new BridgeBio Pharma positions in Q1 2023 and 24 closed out, a net change of +35 holders.
- The largest BridgeBio Pharma buyer in Q1 2023 was Cormorant Asset Management, an estimated $37.2M added.
- The largest BridgeBio Pharma seller in Q1 2023 was State Street, an estimated $43.2M sold.
Based on aggregated 13F filings for Q1 2023.